CD19 and leukemia: Therefore, the expression of orthogonal human IL-2Rβ on CD19-CAR-T cells allows for controllable expansion upon administration of orthogonal human IL-2, which leads to enhanced antitumor activity against leukemia and lymphoma (86, 87).